Investigational drug · Phase 3
Cevostamab
Also called: RO7187797
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
14
Any phase or sponsor naming "Cevostamab"
First trial start
2022
Oct 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Cevostamab", any sponsor or status.
- Phase 111
Conditions studied
As listed on its trial records.
- Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Cevostamab" as an intervention, largest first.
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07555938 · 380 participants (planned) · Start Jun 23, 2026 · Primary completion Nov 30, 2028
Drug: Cevostamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; New Haven, Connecticut · 105 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03275103 · 355 participants · Start Sep 19, 2017 · Primary completion Jan 7, 2026
Drug: Cevostamab; Tocilizumab · For: Multiple Myeloma
Sites: Birmingham, Alabama; Scottsdale, Arizona; Duarte, California · 17 sites in all
Regeneron PharmaceuticalsRegeneron (REGN)
NCT05137054 · 317 participants (planned) · Start Aug 17, 2022 · Primary completion Mar 25, 2028
Drug: Linvoseltamab; Daratumumab and 9 more · For: Multiple Myeloma
Sites: La Jolla, California; Atlanta, Georgia; Indianapolis, Indiana · 42 sites in all
- A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07342114 · 240 participants (planned) · Start Mar 11, 2026 · Primary completion Jun 17, 2030
Drug: RO7875913; Placebo and 1 more · For: Healthy Volunteers; Relapsed Multiple Myeloma; Refractory Multiple Myeloma
Sites: Christchurch, New Zealand
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05583617 · 200 participants (planned) · Start Nov 14, 2023 · Primary completion Jul 31, 2028
Drug: Cevostamab; Lenalidomide and 3 more · For: Multiple Myeloma
Sites: Randwick, Australia; Fitzroy, Australia; Pierre-Bénite, France · 16 sites in all
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04910568 · 186 participants (planned) · Start Jul 26, 2021 · Primary completion Dec 21, 2028
Drug: Cevostamab; Tocilizumab and 3 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; Denver, Colorado · 34 sites in all
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)Pivotal-lookingRecruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05927571 · 120 participants (planned) · Start Aug 10, 2023 · Primary completion Jul 31, 2027
Drug: Cevostamab; Elranatamab and 1 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Camperdown, Australia; Waratah, Australia; Adelaide, Australia · 14 sites in all
Canadian Myeloma Research GroupAcademic, hospital or other
NCT07831122 · 108 participants (planned) · Start Dec 2026 · Primary completion Jan 2033
Drug: Belamaf; Cevostamab and 1 more · For: Relapsed Refractory Multiple Myeloma (RRMM)
Sites: Edmonton, Canada; Halifax, Canada; London, Canada · 7 sites in all
- A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple MyelomaActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05535244 · 90 participants (planned) · Start Oct 17, 2022 · Primary completion Feb 26, 2027
Drug: Cevostamab; Tocilizumab · For: Multiple Myeloma
Sites: Aurora, Colorado; Jacksonville, Florida; Baltimore, Maryland · 27 sites in all
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05646836 · 90 participants (planned) · Start Mar 21, 2023 · Primary completion Nov 18, 2026
Drug: Cevostamab; XmAb24306 and 1 more · For: Multiple Myeloma
Sites: Adelaide, Australia; Melbourne, Australia; Vejle, Denmark · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Cohen AD, Richter J, Trudel S, et al. · Nat Med 2026
- T-Cell Engagers Targeting BCMA, GPRC5D, or FcRH5 in Relapsed/Refractory Multiple Myeloma: The Landscape Beyond CAR-T Cell Therapy-A Systematic Review and Network Meta-Analysis.
Shambhavi S, Joy AA, Singh H, et al. · Int J Mol Sci 2026
- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.
Cohen AD, Richter J, Trudel S, et al. · Nat Med 2026
- Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.
Awadallah C, Zayad A · Oncology (Williston Park) 2026
- Atypical Lymphocytosis Induced by T Cell-Engaging Therapy in Patients With Hematological Malignancies.
Kim TS, Kim HK, Kim SY, et al. · Int J Lab Hematol 2026
- Endless possibilities and how to exploit them? What is the optimal treatment sequence?
Chakraborty R, Bhutani D, Lentzsch S · Hematology Am Soc Hematol Educ Program 2025
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.